



HEALTH & BEAUTY

Q4 2024

**UNAUDITED CONSOLIDATED
REPORT**

LR HEALTH & BEAUTY GROUP

UNAUDITED REPORT

LR HEALTH & BEAUTY SE



HEALTH & BEAUTY

“
OUR VISION IS TO
BE THE WORLD’S MOST
ATTRACTIVE COMPANY
IN SOCIAL COMMERCE.

OUR MISSION IS
TO OFFER PEOPLE THE
CHOICE TO LIVE
A SELF-DETERMINED
LIFE. WE SUCCEED
BECAUSE OF OUR
BUSINESS OPPORTUNITY
AND HIGH-QUALITY
HEALTH AND BEAUTY
SOLUTIONS.

WE
BELIEVE
IN
MORE



**WE BELIEVE
IN MORE
QUALITY
FOR YOUR
LIFE**



FINANCIAL HIGHLIGHTS LR HEALTH & BEAUTY GROUP

in EUR m	Q4 2024	Q4 2023	FY 2024	FY 2023
Sales*	76,5	70,9	289,2	276,5
EBITDA	8,3	9,0	27,3	31,4
EBITDA normalized in % of Sales	9,5 12,4%	10,2 14,4%	32,6 11,3%	35,4 12,8%
Free Cashflow	11,8	9,1	21,4	7,0
Cost of materials	(13,1)	(11,6)	(50,6)	(53,4)
Personnel expenses	(13,9)	(13,2)	(57,0)	(53,5)
Other operating expenses	(43,0)	(38,3)	(155,5)	(146,6)

IR.LRworld.com

*Sales as revenue from goods sold

UNAUDITED CONSOLIDATED INTERIM REPORT Q4 2024 CONTENT

01 FINANCIAL HIGHLIGHTS LR HEALTH & BEAUTY GROUP	04–05
02 WE BELIEVE IN MORE STABILITY	08–13
03 WE BELIEVE IN MORE INTERNATIONALITY	14–17
04 LR HEALTH & BEAUTY GROUP MANAGEMENT REPORT & FINANCIAL STATEMENTS	18–39
05 LR HEALTH & BEAUTY SE MANAGEMENT REPORT & FINANCIAL STATEMENTS	40–47



02

WE BELIEVE IN MORE STABILITY

IN 1985 LR STARTED AS A COMPANY WITH FIVE EMPLOYEES. NOW WE ARE ONE OF THE LEADING EUROPEAN SOCIAL COMMERCE COMPANIES IN THE FIELD OF HEALTH AND BEAUTY PRODUCTS. AND THE STABLE GROWTH OF MORE INTERNATIONALITY, QUALITY, RESPONSIBILITY AND OPPORTUNITIES STILL CONTINUES.


MORE QUALITY FOR YOUR LIFE

WE CARE FOR PEOPLE'S LIVES



SINCE **39**
YEARS SUCCESSFUL
IN EUROPE

AROUND **1,200**
EMPLOYEES



LR Health & Beauty headquarters in Ahlen, Germany

OUR COMPANY

The LR Group is one of the leading social commerce companies that distributes approx. 200 different products from the areas of nutritional supplements and cosmetic products in 32 countries through its hundreds of thousands registered distributors.

LR is a member of the European association Direct Selling Europe (DSE) and has around 1,200 employees across the globe. With quality "Made in Germany" and a unique business model, we have been a successful European business for almost 40 years.

In 2022, Dr Andreas Laabs took over the role of Chief Executive Officer. Dr Laabs, who has already been part of LR as managing director since 2014, is successfully driving the development of the LR Group together with Andreas Grootz, General Manager Legal & New Markets, Patrick Sostmann, General Manager Sales & Marketing and Thomas Heursen, General Manager Global Partner Relations, as well as his entire management team.

In February 2021 LR Global Holding GmbH successfully entered the capital market by issuing a bond. This bond was redeemed in 2024 and a new one was issued by the parent company, LR Health & Beauty SE. In the past years, LR continued its dynamic growth course in order to further develop LR into a leading social commerce company. To this end, LR's structures were further aligned with the digitization trend in the market (e. g. LRneo with all its digital tools) and new blockbuster products were continuously launched.

Despite external circumstances such as the war in Ukraine, high inflation rates and cautious consumer sentiment, LR was able to further stabilize and increase its growth trend in 2024 and achieved a sales growth of 5%.

Thanks to our unique business opportunity and our innovative and competent health and beauty solutions, we sustainably improve the quality of life for many people. With an individual career program,

targeted training, excellent service and a wide range of training tools, we have been leading our distributors to business success for almost 40 years. Our customers should feel healthy and beautiful when using our products. Irrespective of place, time, economic crises or other external challenges, we are offering an attractive and individual purchasing experience on our digital social commerce platforms – 24/7.

OUR SOCIAL COMMITMENT: LR GLOBAL KIDS FUND E.V.

"More quality for your life" not only applies to the products and the business model, but also to the social commitment of LR Health & Beauty. The charity, founded in 2009 and since September 2022 under the leadership of Kirsten Ueckmann as Chairwomen, is based on the collective commitment of the company, its employees, distributors and customers and supports children's aid projects in many LR countries.

OUR VISION & MISSION

“ Our VISION is to be the world's most attractive company in social commerce. Our MISSION is to offer people the best choice to live a self-determined life. We succeed because of our business opportunity and high-quality health and beauty solutions.

MORE STABILITY



OUR INNOVATIVE PRODUCTS

Our product portfolio comprises cutting-edge health and beauty solutions that combine natural ingredients with scientific innovation. This includes care products and decorative cosmetics, perfumes and nutritional supplements. In our modern aloe vera production facility with innovative high-tech machinery, we produce high-quality aloe vera drinking gels with up to 98 % aloe vera leaf fillet content, setting standards throughout Europe. At the company's own development center, experts from the fields of cosmetics and health constantly research and work on new solutions and products. Numerous marketing awards and certificates by renowned German institutes such as SGS INSTITUT FRESENIUS or Dermatest, confirm the high quality and innovative strength of our products. The secret to our success? We have always banked on the quality principle "Made in Germany" and manufacture over 90% of our products in Germany. The high product quality is ensured by strict internal controls and double-checked by

renowned and independent laboratories. We do not use animal testing and set great store by using reusable raw materials. We also promote environmentally friendly production processes and energy-saving logistics solutions.

With the LR ZEITGARD Pro Cosmetic Device launched in autumn 2022, LR achieved a quantum leap in apparative cosmetics. It is an innovative 4-in-1 device and a perfect recruiting tool for our distributors worldwide.

In January 2023 we had the next big launch: LR FIGUACTIVE. The products are better than ever and within the brand LR BODY MISSION, the high quality products offer everyone the smart way to a good body feeling. We achieved another successful launch in September 2023 with our 'Mind Master Formula Gold' product – a daily drink containing a unique formula of vitamins, energy nutrients and antioxidants for mental well-being.

In April 2024 we launched a very successful product concept, the LR HEALTH MISSION – a well thought-out 3 to 6-months support for intestinal, liver and cell metabolism. Most recently in September 2024 we presented our new premium make-up brand LR ZEITGARD Signature – a high-end cosmetic line with state-of-the-art make-up essentials for all skin tones, created by make-up artists.

OUR BUSINESS CONCEPT

For almost 40 years, we have been giving people the opportunity to shape their lives independently and successfully by becoming LR distributors. Thousands of LR distributors have achieved financial freedom and a better quality of life thanks to LR. They are all part of an international team that has established LR's success with a modern sales system, digital possibilities, enthusiasm for fantastic products and plenty of passion.

The LR business model offers independence coupled with the security of a large company that supports its partners in all phases of their careers. Also in difficult times, like in the past three years, this concept has proven to work well – an added bonus is the team spirit in the LR community.

In September 2024 we presented a unique new program, the LR BUSINESS TRACK with a guaranteed monthly bonus. This innovation in the LR career plan is a sensation in social commerce and a real game changer for our business. Because with a steady income stream the LR business is even more predictable and offers our partners the opportunity to concentrate fully on their job.

The merging of offline and online activities has become daily business for the partners. Working with social media platforms in particular has proven to be very efficient. It gives every partner the opportunity to quickly and easily get in touch with other people who have the same interests. Therefore, social media is a success factor and unlocks unlimited potential for direct sales to promote their business.

OUR AWARDS

2023 GERMAN INNOVATION AWARD 2023 SPECIAL

LR received the German Innovation Award 2023 for the Zeitgard Pro Cosmetic Device. The German Innovation Award honours products, technologies and services every year that distinguish themselves through new, innovative features.

2023 GERMAN DESIGN AWARD SPECIAL 2023

LR received the German Design Award 2023 for the Zeitgard Pro Cosmetic Device in the category "Bath and Wellness". The device convinced the top-class jury in the "Excellent Product Design" competition with its modern and timeless product design.

2021 COMPANY AWARD FEDERAL ASSOCIATION OF DIRECT SELLING GERMANY

LR has been awarded second place in the category "Large Companies" in 2021, which means that LR achieved the second strongest sales growth in this category in 2020.

2021 TOP 100 AWARD

LR Health & Beauty Germany has received the Top 100 Award for 2021 – an award for the 100 most innovative, medium-sized companies in Germany.






WE BELIEVE IN MORE INTERNATIONALITY

WITH OUR INTERNATIONAL SUBSIDIARIES
IN 32 COUNTRIES, AROUND 1,200 EMPLOYEES
AND THOUSANDS OF INDEPENDENT
DISTRIBUTORS, WE ARE ONE OF THE LEADING
SOCIAL COMMERCE COMPANIES IN EUROPE.

MORE INTERNATIONALITY

OUR SALES COMPANIES IN 32 COUNTRIES



INTERNATIONAL SALES COMPANIES

WESTERN EUROPE



- AUSTRIA**
LR Health & Beauty Systems GmbH
- BELGIUM / LUXEMBOURG**
LR Cosmetic Belgium b.v.b.a
- DENMARK**
LR Health & Beauty Systems ApS
- ENGLAND / NORTHERN IRELAND / SCOTLAND / WALES**
LR Health & Beauty Limited
- FINLAND**
LR Health & Beauty Systems OY
- FRANCE**
LR Health & Beauty Systems SAS
- GERMANY**
LR Deutschland GmbH
- ITALY**
LR Health & Beauty Systems S.R.L.
- NETHERLANDS**
LR Health & Beauty Systems BV
- NORWAY**
LR Health & Beauty Systems AS
- PORTUGAL**
L. de Racine Cosmetics Lda.
- SPAIN**
LR Health & Beauty Systems S.L.
- SWEDEN**
LR Health & Beauty Systems AB
- SWITZERLAND**
LR Health & Beauty Systems AG
- TURKEY**
LR Health & Beauty Systems Ltd.

CENTRAL EASTERN EUROPE

- ALBANIA**
LR Health & Beauty Systems Sh.p.k.
- BULGARIA**
LR Health & Beauty Systems EOOD
- CZECH REPUBLIC**
LR Health & Beauty Systems s.r.o.
- GREECE / CYPRUS**
LR Health & Beauty Systems EPE
- HUNGARY**
LR Health & Beauty Systems Kft.
- POLAND**
LR Health & Beauty Systems Sp. z.o.o
- ROMANIA**
LR Health & Beauty Systems S.R.L.
- RUSSIA / KAZAKHSTAN**
LR Russ O.O.O
- SLOVAKIA**
LR Health & Beauty Systems s.r.o
- UKRAINE**
LR Health & Beauty Systems TOV

EXPANSION

- SOUTH KOREA**
LR Health & Beauty LLC, South Korea



LR GROUP HEADQUARTER IN GERMANY

- LR Health & Beauty SE
- LR Global Holding GmbH
- LR Health & Beauty Systems Beteiligungs GmbH
- LR International Beteiligungs GmbH
- LR Partner Benefits GmbH
- LR Health & Beauty Systems GmbH
- Divanno Grundstücksverwaltungsgesellschaft mbH & Co. Vermietungs KG
- LR Jersey Holding Limited, Jersey



LR HEALTH & BEAUTY GROUP

MANAGEMENT REPORT & FINANCIAL STATEMENTS



MANAGEMENT REPORT

LR Health & Beauty Group (hereinafter referred to as “LR Group”, “LR” or “the Group”) with its parent company LR Health & Beauty SE (hereinafter referred to as “LR SE”) is an internationally operating enterprise with a primary focus on cosmetics and dietary supplements. LR Group is represented by 34 companies in 32 countries worldwide and markets its products through direct sales on the European and Asian Social Commerce markets. The Group’s production sites are located in Ahlen (Germany) and all subsidiaries are supplied from Ahlen.

SALES AND OTHER INCOME

In the fourth quarter of 2024 (Q4 2024), LR Group achieved a sales volume of kEUR 76,541. This represents an increase of 8.0% compared to the fourth quarter of the previous year (Q4 2023: kEUR 70,853). In the full year 2024 (FY 2024), sales increased by 4.6% to kEUR 289,221 compared to the financial year 2023 (FY 2023) with kEUR 276,474. Overall, this was the second-best fourth quarter result in the company’s history. This continues the growth trend from the previous financial year 2023 and the first nine months of 2024.

An important driver for the positive sales development is the consistent implementation of the strategic measures developed over the past two years with a focus on the business opportunities of our distributors. The number of careers of our distributors has increased significantly, resulting in improved sales levels. In addition, the revised concept for our product launches also supported the positive development. Following the successful launch of the new drink “Mind Master Gold” in September 2023, which was met with great

demand, another very successful product concept, the “LR HEALTH MISSION”, was launched in April 2024. The latest product launch took place at the end of September 2024: LR ZEITGARD Signature, a high-quality make-up range, reduced to the essentials with great effect. All three launches have met the needs of distributors very well and are among the five most successful launches in LR history.

For efficient management, the LR Group is organized into two regions:

- Region Western Europe comprises Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, Norway, Portugal, Spain, Sweden, Switzerland, the Netherlands, Turkey, and the United Kingdom.
- Region Central Eastern Europe comprises Albania, Bulgaria, Cyprus, the Czech Republic, Greece, Kazakhstan, Hungary, Poland, Romania, Russia, Slovakia, and Ukraine.

Both regions recorded positive sales growth in the past quarter as well as in the full year 2024. Region Western Europe, including LR’s home market in Germany, increased by +3.2% to kEUR 44,674 in Q4 2024 compared to kEUR 43,280 in Q4 2023 and by +3.2% to kEUR 174,635 in FY 2024 compared to kEUR 169,211 in FY 2023. Sales in region Central Eastern Europe increased by +16.3% to kEUR 31,731 in Q4 2024 compared to kEUR 27,278 in Q4 2023 and by +7.9% to kEUR 113,903 in FY 2024 compared to kEUR 105,534 in FY 2023.

¹Sales as revenue from goods sold

LR HEALTH & BEAUTY GROUP

Other revenue amounts to kEUR 4,060 in the fourth quarter (Q4 2024: kEUR 4,122) and to kEUR 11,455 in FY 2024 (FY 2023: kEUR 12,280). Adding total sales and other revenues results in revenues before sales deductions of kEUR 80,601 for Q4 2024 and of kEUR 300,676 for FY 2024. After sales deductions in the amount of kEUR –2,598 in Q4 2024 and of kEUR –14,651 in FY 2024, revenue amounts to kEUR 78,003 in Q4 2024 and to kEUR 286,025 in FY 2024. Other operating income in the fourth quarter of 2024 amounted to kEUR 1,953 (Q4 2023: kEUR 2,046) and in the financial year 2024 to kEUR 6,732 (FY 2023: kEUR 6,279).

COST STRUCTURE

LR Group's cost of materials increased by kEUR 1,476 to kEUR 13,092 in the fourth quarter of 2024 (Q4 2023: kEUR 11,616) but decreased by kEUR 2,810 to kEUR 50,587 in FY 2024 (FY 2023: kEUR 53,397). With the planned reduction in inventories especially in the first half year, changes in finished goods and work in progress amount to kEUR –1,600 in Q4 2024 (Q4 2023: kEUR –1,188) and to kEUR –2,287 in FY 2024 (FY 2023: kEUR +4,207). The total of cost of materials and changes in finished goods and work in progress increased to kEUR 14,692 in Q4 2024 (Q4 2023: kEUR 12,804) and to kEUR 52,874 in FY 2024 (FY 2023: kEUR 49,190). In relation to sales, this corresponds to increased ratios of 19.2% in Q4 2024 (Q4 2023: 18.1%) and of 18.3% in FY 2024 (FY 2023: 17.8%).

Personnel expenses increased in the fourth quarter of 2024 to kEUR 13,939 (Q4 2023: kEUR 13,193) and in the full year 2024 to kEUR 57,008 (FY 2023: kEUR 53,521). The headcount stood at 1,204 as of December 31, 2024. This corresponds to a decrease compared to the end of the previous quarter (1,211 as of September 30, 2024) and to the end of the previous year (1,222 as of December 31, 2023). One of the main drivers for the 5.7% increase in personnel costs in the fourth quarter

and the 6.5% increase in the full year 2024 is the one off inflation compensation premium paid out in Germany.

Other operating expenses increased to kEUR 43,029 in the fourth quarter of 2024 compared to kEUR 38,273 in the previous year and over the year to kEUR 155,546 from kEUR 146,632 in the previous year. This increase is caused by legal and consulting fees, in conjunction with the issue of the corporate bond, and higher costs for bonus payments to distributors. The increase in bonus costs is due to increased sales and preparatory measures for a major change to the career plan that came into effect in October 2024, which led to a significant increase in new distributors. The realignment of the career plan for distributors aims to continue the strategy of focusing on business opportunity and is intended in particular to strengthen full-time distributors and facilitate entry as a full-time distributor, while at the same time reducing scatter losses.

ECONOMIC RESULTS

Q4 2024 closed with a decreased reported EBITDA of kEUR 8,296 compared to Q4 2023 with kEUR 8,973 and kEUR 27,329 for FY 2024 compared to kEUR 31,413 in the previous year. This is mainly caused by the increased personnel costs and other operating expenses. Taking into account exceptional items of kEUR 1,222 in Q4 2024 and kEUR 5,243 for FY 2024, the normalized EBITDA amounted to kEUR 9,518 (Q4 2023: kEUR 10,180) and to kEUR 32,572 in the full year 2024 (FY 2023: kEUR 35,380). Deducting amortization and depreciation in the amount of kEUR 2,927 in Q4 2024 (Q4 2023: kEUR 3,459) and kEUR 12,818 for FY 2024 (FY 2023: kEUR 13,212) from the reported EBITDA results in an EBIT of kEUR 5,369 in Q4 2024 (Q4 2023: kEUR 5,514) and of kEUR 14,511 in FY 2024 (FY 2023: kEUR 18,201).

The financial result, including interest expenses for the corporate bond, which increased with the nominal value and the one-off expense resulting from the repayment of the corporate bond of LR Global Holding GmbH in the first quarter in the amount of 101.45% of the nominal value, increased to kEUR –4,617 in Q4 2024 (Q4 2023: kEUR –4,458) and to kEUR –21,219 in FY 2024 (FY 2023: kEUR –15,836). After deducting income taxes in the amount of kEUR –2,684 for Q4 2024 (Q4 2023: kEUR –1,939) and of kEUR –5,115 for FY 2024 (FY 2023: kEUR –3,230), the loss for the period amounts to kEUR –1,932 for the fourth quarter of 2024 (Q4 2023: kEUR –883) and to kEUR –11,823 in FY 2024 (FY 2023: kEUR –865).

FINANCIAL STATUS

Overall, total assets decreased from kEUR 234,702 as of December 31, 2023, to kEUR 225,487 as of December 31, 2024. Non-current assets remained almost stable at kEUR 152,218 compared to kEUR 151,198 at the end of the previous year. Current assets decreased by kEUR 10,235 to kEUR 73,269 at the end of the financial year 2024 compared to kEUR 83,504 at the previous year end. Inventories were reduced as planned and now amount to kEUR 26,724. This corresponds to a decrease of kEUR 7,888 compared to kEUR 34,612 as of December 31, 2023. Trade receivables increased by kEUR 767 to kEUR 14,591 as of December 31, 2024, compared to kEUR 13,824 as of December 31, 2023. The cash level decreased from kEUR 23,955 at the end of the previous year to kEUR 19,641 as of December 31, 2024.

The equity position has been impacted by two effects. On the one hand, the capital reserve was improved by kEUR 1,376 due to the reclassification of the shareholder loan. On the other hand, equity was reduced by the negative total comprehensive income of kEUR –13,345, resulting in total equity of kEUR 15,260 as of December 31, 2024. This corresponds to an equity share of 6.8%. Adding



the remaining part of the shareholder loan results in economic equity of kEUR 18,132, which corresponds to an economic equity ratio of 8.0%.

The structure of the liabilities is mainly characterized by liabilities from bonds. On February 19, 2024, LR SE placed a senior secured corporate bond (ISIN: NO0013149658) with a nominal issue volume of EUR 130 million and issue proceeds of approximately EUR 125 million. These proceeds were used to refinance the existing 2021/2025 bond of LR Global Holding GmbH (ISIN NO0010894850). In this context, a loan agreement was concluded between LR Global Holding GmbH and LR Health & Beauty SE on March 1, 2024. The bond is issued in the so-called "Nordic bond format" under Swedish law and with the involvement of Nordic Trustee & Agency AB as trustee. The bond bears interest at 7.5% + 3M EURIBOR (with a floor of zero) and matures on March 6, 2028. It is traded in the Open Market of the Frankfurt Stock Exchange. The terms of the corporate bond require a listing on the regulated market of Nasdaq Stockholm within

LR HEALTH & BEAUTY GROUP

twelve months of the issue date. Non-current liabilities increased to kEUR 154,373 as of December 31, 2024, compared to kEUR 150,951 at the end of the previous year mainly by two effects. On the one hand, the deferred taxes increased by kEUR 2,052 and on the other hand, a new shareholder loan with an interest rate of 0.5% and a due date of March 30, 2028 was granted by Aloco Holding S.à. r.l. on March 7, 2024. Due to partial reclassification to the capital reserve in the amount of kEUR 1,376, the carrying amount of the subordinated loan with a nominal value of kEUR 4,000 amounts to kEUR 2,872. Current liabilities slightly decreased to kEUR 55,854 as of December 31, 2024 compared to kEUR 56,522 as of December 31, 2023.

Cash flow from operating activities increased to kEUR 13,654 in Q4 2024 from kEUR 10,892 in Q4 2023 and to kEUR 26,962 in the full year 2024 from kEUR 12,874 in FY 2023, which was impacted by subsequent tax payments for previous years. All other major factors affecting operating cash flow, such as profit, changes in inventories or trade receivables and trade payables, are described in the sections above. Cash flow from investing activities amounted to kEUR -1,880 in Q4 2024 (Q4 2023: kEUR -1,775) and to kEUR -5,601 in FY 2024 (FY 2023: kEUR -5,922) and is therefore almost stable compared to the same periods of the previous year. Free cash flow, including cash flow from operating activities and cash flow from investing activities, increased to kEUR 11,774 in Q4 2024 compared to kEUR 9,117 in Q4 2023 and to kEUR 21,361 in the full year 2024 compared to kEUR 6,952 in FY 2023. Cash flow from financing activities amounted to kEUR -6,189 in Q4 2024 (Q4 2023: kEUR -6,179) and to kEUR -25,925 in FY 2024 (FY 2023: kEUR -23,019). Overall, total cash flow amounted to kEUR 5,585 in the fourth quarter of 2024 (Q4 2023: kEUR 2,938) and to kEUR -4,564 in FY 2024 (FY 2023: kEUR -16,067). Including changes in cash due to exchange rates, cash amounted to kEUR 19,641 as of December 31, 2024.

OUTLOOK / GUIDANCE

Based on these unaudited results, LR was able to achieve the forecast for sales (revenue from goods sold) ranging from kEUR 288,000 to kEUR 292,000 with Group-wide sales of kEUR 289,221. The EBITDA forecast in the issued range of kEUR 26,000 to kEUR 29,000 was also achieved at kEUR 27,329.

The guidance for sales and EBITDA for 2025 will be published together with the 2024 annual financial statements (scheduled for the end of April 2025).

Munich, February 27, 2025

LR Health & Beauty SE
- Executive Board -


Dr. Andreas Laabs
(CEO)



Andreas Grootz
(General Manager)



DR. ANDREAS LAABS
CEO



ANDREAS GROOTZ
GENERAL MANAGER



LR HEALTH & BEAUTY GROUP

CONDENSED CONSOLIDATED BALANCE SHEET AS OF DEC 31, 2024

kEUR	Note	Dec. 31, 2024	Dec. 31, 2023
Non-current assets			
Intangible assets		120,705	119,372
Property, plant and equipment	7.	12,820	12,966
Right-of-use assets		16,941	17,439
Deferred taxes		1,752	1,421
		152,218	151,198
Current assets			
Inventories	8.	26,724	34,612
Trade receivables	9.	14,591	13,824
Income tax receivables		1,196	308
Other assets		11,201	10,805
Cash	10.	19,641	23,955
		73,353	83,504
TOTAL ASSETS		225,571	234,702

CONDENSED CONSOLIDATED BALANCE SHEET AS OF DEC. 31, 2024

kEUR	Note	Dec. 31, 2024	Dec. 31, 2023
Equity			
Subscribed capital		10,120	10,120
Capital reserve		151,506	150,130
Currency translation reserve		-8,731	-7,209
Accumulated loss		-137,635	-125,812
TOTAL EQUITY		15,260	27,229
Non-current liabilities			
Provisions		447	356
Deferred taxes		5,945	3,893
Liabilities from bonds	9.	124,974	125,490
Liabilities from loans		7,730	8,105
Liabilities from shareholder loans		2,872	0
Lease liabilities		12,119	12,064
Other liabilities		286	1,043
		154,373	150,951
Current liabilities			
Trade payables	9.	34,215	34,748
Other liabilities		9,463	10,250
Lease liabilities		5,842	6,003
Liabilities from loans		374	365
Income tax liabilities		2,820	1,184
Provisions		3,224	3,972
		55,938	56,522
TOTAL EQUITY AND LIABILITIES		225,571	234,702

LR HEALTH & BEAUTY GROUP

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS
FOR THE PERIOD JAN. 1, 2024 TO DEC. 31, 2024

kEUR	Note	Q4 2024	Q4 2023	FY 2024	FY 2023
Revenue	3. to 4.	78,003	71,197	286,025	274,477
Changes in finished goods and work in progress		-1,600	-1,188	-2,287	4,207
Other operating income		1,953	2,046	6,732	6,279
Cost of material		-13,092	-11,616	-50,587	-53,397
a) Raw materials and supplies		-11,070	-9,582	-43,322	-45,706
b) Cost of purchased services		-2,022	-2,034	-7,265	-7,691
Personnel expenses		-13,939	-13,193	-57,008	-53,521
a) Wages and salaries		-11,713	-11,068	-48,194	-45,160
b) Expenses for social security and pension schemes		-2,226	-2,125	-8,814	-8,361
Other operating expenses		-43,029	-38,273	-155,546	-146,632
EBITDA	4.	8,296	8,973	27,329	31,413
Amortization and depreciation		-2,927	-3,459	-12,818	-13,212
Financial result		-4,617	-4,458	-21,219	-15,836
Profit or loss before tax		752	1,056	-6,708	2,365
Income taxes	6.	-2,684	-1,939	-5,115	-3,230
PROFIT OR LOSS FOR THE PERIOD		-1,932	-883	-11,823	-865

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE
INCOME FOR THE PERIOD JAN. 1, 2024 TO DEC. 31, 2024

kEUR	Q4 2024	Q4 2023	FY 2024	FY 2023
Profit or loss for the period	-1,932	-883	-11,823	-865
Components of other comprehensive income which will be reclassified to profit or loss after tax in subsequent periods	38	-435	-1,522	-818
Currency translation differences	38	-435	-1,522	-818
TOTAL COMPREHENSIVE INCOME	-1,894	-1,318	-13,345	-1,683

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD JAN. 1, 2024 TO DEC. 31, 2024

kEUR	Subscribed capital	Capital reserve	Accumulated loss	Currency translation reserve	Total equity
Jan. 1, 2024	10,120	150,130	-125,812	-7,209	27,229
Currency translation differences	0	0	0	-1,522	-1,522
Contribution of the shareholder loan at nominal value	0	1,376	0	0	1,376
Profit or loss for the period	0	0	-11,823	0	-11,823
Dec. 31, 2024	10,120	151,506	-137,635	-8,731	15,260
Jan. 1, 2023	10,120	150,130	-124,947	-6,391	28,912
Currency translation differences	0	0	0	-818	-818
Profit or loss for the period	0	0	-865	0	-865
Dec. 31, 2023	10,120	150,130	-125,812	-7,209	27,229

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE PERIOD JAN. 1, 2024 TO DEC. 31, 2024

kEUR		Q4 2024	Q4 2023	FY 2024	FY 2023
1. Cash flow from operating activities	Note				
Profit or loss for the period		-1,932	-883	-11,823	-865
Amortization and depreciation (+) of fixed assets		2,927	3,459	12,818	13,212
Increase (+) / reduction (-) in provisions		-1,247	-104	-657	-862
Other non-cash expenses (+) / income (-)		348	-2,113	-1,525	-1,807
Income (-) / losses (+) on the disposal of fixed assets		0	5	0	1
Increase (-) / reduction (+) in inventories, trade receivables and other assets		3,460	1,535	6,562	-12,458
Increase (+) / reduction (-) in trade payables and other liabilities		3,391	3,160	-2,226	4,914
Interest expenses (+) / interest income (-)		4,617	4,550	21,219	15,836
Income tax expenses (+) / income (-)	7.	2,684	1,939	5,115	3,230
Income taxes paid (-)		-594	-656	-2,521	-8,327
CASH FLOW FROM OPERATING ACTIVITIES		13,654	10,892	26,962	12,874
2. Cash flow from investing activities					
Payments from (+) the disposal of property, plant and equipment		0	1	2	11
Payments for (-) investments in property, plant and equipment		-464	-751	-1,599	-1,626
Payments for (-) investments in intangible assets		-1,416	-1,025	-4,004	-4,307
CASH FLOW FROM INVESTING ACTIVITIES		-1,880	-1,775	-5,601	-5,922
3. Cash flow from financing activities					
Proceeds (+) from the issue of bonds		0	0	122,135	0
Proceeds (+) from shareholder loan		0	0	4,000	0
Proceeds (+) from interest		72	176	229	176
Repayment (-) of bonds		0	0	-126,813	0
Repayment (-) of loan		-92	-90	-365	-356
Payments for (-) interest		-3,636	-3,652	-15,183	-13,209
Repayment (-) of lease liabilities		-2,533	-2,613	-9,928	-9,630
CASH FLOW FROM FINANCING ACTIVITIES		-6,189	-6,179	-25,925	-23,019
4. Cash at the end of period					
Net increase (+) / decrease (-) in cash		5,585	2,938	-4,564	-16,067
Changes in cash due to exchange rates		297	851	250	604
Cash at the beginning of period		13,759	20,166	23,955	39,418
CASH AT THE END OF PERIOD		19,641	23,955	19,641	23,955

LR HEALTH & BEAUTY SE MUNICH / GERMANY

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. INFORMATION ON THE GROUP

LR Health & Beauty SE (hereinafter referred to as "LR SE") is a European stock corporation incorporated in Germany pursuant to Art. 3 (2) SE Regulation and has its registered office in Munich, Germany, and is registered in the commercial register of Munich under HRB No. 258262. The business address of the company is Kruppstraße 55, 59227 Ahlen, Germany.

LR SE and its subsidiaries (hereinafter jointly referred to as "the Group") are an internationally operating enterprise with a primary focus on cosmetics and dietary supplements. LR SE is represented with 34 subsidiaries worldwide. The Group's production sites are located in Ahlen (Germany). All subsidiaries are supplied from Ahlen. Research and development is also implemented exclusively in Germany.

The Group markets its products through direct sales, with marketing plans focused on the European and Asian markets. The product range comprises dietary supplements, perfumes, cosmetics, and accessories. The Group's business is primarily determined by private consumption and the pertinent cosmetics and food laws.

The ultimate controlling parent company is Alico Holding S.à r.l, with registered office in Luxembourg, Luxembourg.

2. BASIS FOR PREPARING THE FINANCIAL STATEMENTS AND CHANGES TO THE GROUP'S ACCOUNTING POLICIES

a. Basis for preparing the financial statements

The unaudited interim condensed consolidated financial statements for the financial year 2024, have been prepared in accordance with IAS 34 Interim Financial Reporting. They are prepared in line with the International Financial Reporting Standards (IFRS) and its interpretations adopted by the International Accounting Standards Board (IASB) for interim financial information, effective within the European Union. Accordingly, these financial statements do not include all of the information and footnotes required by IFRS for complete financial statements for year-end reporting purposes and should be read in conjunction with the Group's annual consolidated financial statements as of December 31, 2023.

The Group assets were assessed according to the going-concern principle, i.e., with the assumption of continuation of the Company.

The functional currency and reporting currency of the Group is euro (EUR). The consolidated financial statements are prepared in euro, as the majority of transactions within the Group is implemented in said currency. Unless specified otherwise, all values are rounded up or rounded off to full thousand euro (kEUR).

b. New standards, interpretations and amendments adopted by the Group

The accounting policies adopted in the preparation of the unaudited interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group's annual consolidated financial statements for the year ended December 31, 2023. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective or not yet endorsed by the EU.

Several amendments apply for the first time in 2024, but do not have an impact on the unaudited interim condensed consolidated financial statements of the Group.

3. REVENUE FROM CONTRACT WITH CUSTOMERS

Revenues in the regions essentially comprise revenues from products of the Group. Other revenues comprise revenues from services rendered such as cost allocations, seminars, and events as well as revenue of kEUR 4,266 (PY: kEUR 4,763) recognized over time from subleasing vehicles to partners. The revenue reductions mainly comprise revenue-based discounts to partners.

4. OPERATING SEGMENTS

For management purposes, the Group is organized into business units and its respective local companies and establishments are combined into two regions. In some cases, the local companies are assigned to a region geographically, in other cases they are assigned individually.

The two reported regions break down in detail as follows:

Region Western Europe comprises Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, Norway, Portugal, Spain, Sweden, Switzerland, the Netherlands, Turkey and United Kingdom.

Region Central Eastern Europe comprises Albania, Bulgaria, Cyprus, Czech Republic, Greece, Kazakhstan, Hungary, Poland, Romania, Russia, Slovakia and Ukraine.

The regions are managed by the respective vice presidents of the region. The management board of LR SE is the chief operating decision maker, who separately monitors the region's operating results to make decisions about resources to be allocated and assess its performance. For the analysis of business performance and the Group's situation, the management board uses earnings before interest, taxes, depreciation, and amortization (EBITDA) as well as revenue without other revenue and before revenue reductions as financial ratios which are compared with the latest forecast for the reporting period. Group financing (including finance costs, finance income and other income) and income tax expenses are managed on a group basis and are not allocated to operating regions.

Transfer prices between the German production company and the local sales companies are based on the transactional net margin method in accordance with the OECD Guidelines. Transfer prices between the regions are on an arm's length basis in a manner similar to transactions with third parties.

The table below shows revenue, EBITDA, and goodwill of the LR Group's regions for the financial year 2024:

KEUR	Region Western Europe	Region Central Eastern Europe	Total Segments	Adjustments	Total
Revenue external customers	174,635	113,903	288,538	683	289,221
Revenue other segment	43,599	1,926	45,525	-45,525	0
Revenue other	6,991	2,895	9,886	1,569	11,455
Revenue reduction	-8,590	-6,061	-14,651	0	-14,651
TOTAL REVENUE	216,635	112,663	329,298	-43,273	286,025
Segment EBITDA	17,845	8,841	26,686	643	27,329
Goodwill	77,422	24,097	101,519	3	101,522

The table below shows revenue, EBITDA, and goodwill of the LR Group's regions for the financial year:

KEUR	Region Western Europe	Region Central Eastern Europe	Total Segments	Adjustments	Total
Revenue external customers	169,211	105,534	274,745	1,728	276,473
Revenue other segment	40,938	1,668	42,606	-42,606	0
Revenue other	7,305	3,652	10,957	1,325	12,282
Revenue reduction	-8,439	-5,839	-14,278	0	-14,278
TOTAL REVENUE	209,015	105,015	314,030	-39,553	274,477
Segment EBITDA	18,002	11,235	29,237	2,259	31,496
Goodwill	77,422	24,097	101,519	3	101,522

The "Adjustments" column largely contains the Group's holding and management companies as well as eliminations. For a reconciliation of earnings before taxes please refer to the income statement.

5. IMPAIRMENT TESTING OF GOODWILL AND INTANGIBLE ASSETS WITH INDEFINITE LIVES

The Group performed its annual impairment test in December and when circumstances indicated that the carrying value may be impaired or if segments are changed. The Group's impairment test for goodwill and intangible assets with indefinite lives is based on value-in-use calculations. The key assumptions used to determine the recoverable amount units

were disclosed in the annual consolidated financial statements for the year ended December 31, 2023.

For the allocation of goodwill to segments, we refer to note 4.

The last test performed in December 2024 concluded that no impairment is required.

6. INCOME TAX

The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major items of income tax expenses for the financial year 2024 and 2023 are as follows:

KEUR	2024	2023
Current income tax		
Current tax expenses	-3,371	-2,539
Deferred tax result		
Origination and reversal of temporary differences	-1,744	-691
from deferred tax assets	327	37
from deferred tax liabilities	-2,071	-728
TOTAL	-5,115	-3,230

7. PROPERTY, PLANT AND EQUIPMENT

Acquisitions and disposals

During the financial year 2024, the Group acquired assets with total acquisition costs of kEUR 1,599 (2023: kEUR 1,626). The major part of the acquisition belongs to other technical and office equipment.

No major disposal took place in the financial year 2024.

8. INVENTORIES

Inventories are measured at the lower of cost and net realizable value.

KEUR	Dec. 31, 2024	Dec. 31, 2023
Raw materials and supplies	6,247	9,850
Work in progress	394	180
Finished products	15,095	18,133
Goods for sale	4,573	6,226
Goods in transit	415	223
TOTAL INVENTORIES	26,724	34,612

Impairment of inventories recognized as expenditures amounts to kEUR 1,054 (2023: kEUR 1,520)

9. FINANCIAL ASSETS AND FINANCIAL LIABILITIES

All assets and liabilities, for which the fair value is disclosed in the financial statements, are categorized within the measurement hierarchy, described as follows, based on the lowest level input that is significant to the fair-value measurement as a whole:

- Level 1: Quoted (unadjusted) market prices in active markets for identical assets or liabilities
- Level 2: Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable
- Level 3: Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

With the exception of trade receivables, the Group measures financial assets at amortized cost plus transaction costs incurred. Trade receivables are measured at the transaction price.

Financial liabilities are initially measured at fair value or fair value less transaction costs. The Group's financial liabilities include trade payables, lease liabilities, other financial liabilities, bonds, and liabilities from loans.

Due to the maturity, the fair value of the financial assets including trade receivables and cash corresponds to the reported carrying amount. Also, the fair value of the trade payables and the lease liabilities corresponds to the reported carrying amount due to the maturity.

For the interest-bearing financial liabilities, the quantitative disclosures for fair value measurement of liabilities according to hierarchy as of December 31, 2024, as follows:

KEUR	Carrying amount	Fair value measurement using			Total
		Quoted prices in active markets	Significant observable inputs	Significant unobservable inputs	
	Level 1	Level 2	Level 3		
Liabilities for which a fair value is reported					
Interest bearing loans					
Corporate bond 2024/2028	124,974	118,625	0	0	118,625
Fixed-rate loan	8,104	0	7,273	0	7,273
Fixed-rate shareholder loan	2,872	0	2,959	0	2,959

The fair value of the corporate bonds is based on the observed market price of EUR 912,5 per bond as of December 31, 2024.

The determination of the fair value of the fixed-rate loan is based on the development of the interest-yield curve for listed German Federal securities with a twenty-year term to maturity.

The determination of the fair value of the fixed-rate shareholder loan is based on the interest rate of the corporate bond as the issue date and duration is nearly the same.

For the interest-bearing financial liabilities, the quantitative disclosures for fair value measurement of liabilities according to hierarchy as of December 31, 2023, as follows:

KEUR	Carrying amount	Fair value measurement using			Total
		Quoted prices in active markets	Significant observable inputs	Significant unobservable inputs	
	Level 1	Level 2	Level 3		
Liabilities for which a fair value is reported					
Interest bearing loans					
Corporate bond 2021/2025	125,490	122,813	0	0	122,813
Fixed-rate loan	8,470	0	7,847	0	7,847

The fair value of the corporate bonds is based on the observed market price of EUR 982.50 per bond as of December 31, 2023

Financial liabilities

On February 19, 2024, LR SE placed a senior secured corporate bond (ISIN: NO0013149658) with a nominal issue volume of EUR 130 million and issue proceeds of approximately EUR 125 million. These proceeds were be used to refinance the existing 2021/2025 bond of LR Global Holding GmbH (ISIN NO0010894850). In this context, a loan agreement was concluded between LR Global Holding GmbH and LR Health & Beauty SE on March 1, 2024. Like the 2021/2025 bond, the bond 2024/2028 is issued in the so-called "Nordic bond format" under Swedish law and with the involvement of Nordic Trustee & Agency AB as trustee. The bond is traded in the Open Market of the Frankfurt Stock Exchange. The terms of the corporate bond require a listing on the regulated market of Nasdaq Stockholm within twelve months of the issue date. On March 11, 2024, the senior secured bond 2021/2025 of LR Global Holding GmbH was fully repaid. The delisting of the bond 2021/2025 from the Nasdaq Stockholm took place on March 7, 2024.

The bond 2024/2028 bears interest at EURIBOR +7.50% (with a floor of zero). Interest is payable every three months. The bond 2024/2028 matures on March 6, 2028. The effective interest rate of the bond is currently 10.412%.

The Group companies have deposited collateral in this context. In addition, covenants in the form of a leverage ratio and a pre-IFRS 16 leverage ratio were agreed. The Group performs quarterly a maintenance test if these covenants are met. For the fourth quarter ended December 31, 2024, the covenants are met.

As of December 31, 2024, the carrying amount of the liabilities from the bond 2024/2028 was kEUR 124,974 and included accrued interest and capitalized transaction costs.

For further information regarding the fixed-rate shareholder loan, please refer to Note 11.

10. CASH

The Group has pledged a part of its cash at banks to fulfill collateral requirements.

Cash comprised the following as of December 31, 2024, and December 31, 2023:

KEUR	Dec. 31, 2024	Dec. 31, 2023
Cash at hand	90	66
Cash at banks	19,551	23,889
CASH	19,641	23,955

11. RELATED PARTY DISCLOSURES

For the Group, related companies and parties pursuant to IAS 24 are companies or parties which directly or indirectly control or are controlled by the Group or are under the joint control of and/or significantly influence the Group or are significantly influenced by the latter as well as members of the management in key positions.

Accordingly, the direct and ultimate parent company of LR SE, Aloco Holding S.à r.l., Luxembourg, Luxembourg, members of the management board as well as their relatives, members of the LR Health & Beauty SE supervisory board and subsidiaries of the Group are defined as related companies or parties.

On March 7, 2024, LR SE and Aloco Holding S. à. r. l. closed a fixed-rate shareholder loan agreement about an amount of 4 million Euro. The loan bears an interest rate of 0.5% p. a. The loan and the related interest are due March 30, 2028. Full or partial redemption of the loan is allowed at any time. Upon initial recognition, the loan is measured at a fair market interest rate, as the interest rate does not comply to the “at arm’s length” principle compared to the interest rate of the simultaneously issued bonds in the amount of 3-Months-EURIBOR +7.5%. The difference resulting from the valuation amounts to KEUR 1,376. As the loan is a transaction with the shareholders, the difference resulting from the valuation is recognized as a contribution to capital reserve. As a result of the valuation, the loan is subject to interest at the fair market interest rate.

For the financial year 2024 the related interest expense amounts to KEUR 248 (PY: KEUR 0). As of December 31, 2024, the carrying amount of the loan was KEUR 2,872 (PY: KEUR 0) including accrued interests.

Remuneration to individuals in key positions of the Group

KEUR	2024	2023
Short-term employee benefits	7,144	7,508
TOTAL REMUNERATION TO INDIVIDUALS IN KEY POSITIONS OF THE GROUP	7,144	7,508

The amounts shown in the table were recognized as expenditure in the reporting period in connection with individuals in key positions.

Munich, February 27, 2025

LR Health & Beauty SE
- Executive Board -

Dr. Andreas Laabs
(CEO)

Andreas Grootz
(General Manager)





LR HEALTH & BEAUTY SE

MANAGEMENT REPORT & FINANCIAL STATEMENTS

MANAGEMENT REPORT

LR Health & Beauty SE (hereinafter referred to as "LR SE") is a European stock corporation incorporated in Germany with its registered office in Munich, Germany, while the business address of the company is Kruppstrasse 55, 59227 Ahlen, Germany. LR SE is a holding company and holds direct or indirect shares in 33 active subsidiaries. LR SE and its subsidiaries (hereinafter jointly referred to as "LR Group", "LR Health & Beauty Group", or "the Group") are an internationally operating enterprise with a primary focus on cosmetics and dietary supplements.

In the fourth quarter of 2024 (Q4 2024), LR SE's revenues increased to kEUR 455 compared to kEUR 348 in the fourth quarter of the previous year (Q4 2023). In the full year (FY 2024), revenues amounted to kEUR 1,552 compared to kEUR 1,015 in the financial year 2023 (FY 2023). This mainly results from cost allocations to LR Health & Beauty Systems GmbH, Ahlen, for services rendered. Other operating income amounted to kEUR 22 in Q4 2024 (Q4 2023: kEUR 1) and to kEUR 46 in FY 2024 (FY 2023: kEUR 64).

Personnel expenses increased from kEUR 253 in Q4 2023 to kEUR 362 in Q4 2024 and from kEUR 951 in FY 2023 to kEUR 1,537 in FY 2024. Other operating expenses at LR SE, including legal and consulting fees, allowances for the Supervisory Board and travel expenses, amounted to kEUR 198 in the fourth quarter of 2024 and to kEUR 1,563 in the full year 2024, both significantly higher than in the previous year. The high increase resulted mainly from legal and consulting fees related to the issuance of the corporate bond.

The financial result amounted to kEUR -2,539 in Q4 2024 (Q4 2023: kEUR 0) and to kEUR -3,757 in FY 2024 (FY 2023: kEUR 0). It mainly results from the assumption of losses from the profit and loss transfer agreement with LR Global Holding

GmbH, from interest expenses of the corporate bond and from interest income from the intercompany loan to LR Global Holding GmbH.

Income taxes amounted to kEUR 6,612 in Q4 2024 (Q4 2023: kEUR 0) and FY 2024 (FY 2023: kEUR 0). Overall, the net loss of the fourth quarter 2024 amounted to kEUR -9,234 (Q4 2023: kEUR 92) and in full year to kEUR -11,871 (FY 2023: kEUR -83).

Total assets as of December 31, 2024 increased to kEUR 286,596 compared to kEUR 153,218 as of December 31, 2023 (PY). This significant increase is caused by the issuance of the corporate bond and by the granting of an intercompany loan to LR Global Holding GmbH. The latter is reflected in the non-current assets, which increased from kEUR 152,458 as of December 31, 2023, to kEUR 281,273 as of December 31, 2024. In addition to the shares in affiliates, which remained constant at kEUR 152,458, these also include the new intercompany loan with a carrying amount of kEUR 128,815. Current assets increased from kEUR 760 as of December 31, 2023, to kEUR 1,146 as of December 31, 2024. This includes receivables from affiliates in the amount of kEUR 1,067 (PY: kEUR 619). In August 2024, LR SE was included in a cash pooling agreement with LR Health & Beauty Systems GmbH (cash pool leader), thus reducing the cash balance to kEUR 0 at the end of Q4 2024 (PY: kEUR 141). Prepaid expenses include the original issue discount on the corporate bond with a carrying amount of kEUR 4,177 (PY: kEUR 0; valuation according to German GAAP/Handelsgesetzbuch differs from IFRS valuation in the Group reporting).

Equity decreased by the net loss for the full year 2024 of kEUR -11,871, from kEUR 152,197 as of December 31, 2023, to kEUR 140,326 as of December 31, 2024.

Provisions increased from kEUR 451 as of December 31, 2023, to kEUR 2,281 as of December 31, 2024, including tax provisions in the amount of kEUR 1,362 (PY: kEUR 0). Liabilities increased from kEUR 570 as of December 31, 2023, to kEUR 138,765 as of December 31, 2024. This significant increase is related to liabilities to shareholders in the amount of kEUR 4,016 (valuation according to German GAAP/Handelsgesetzbuch differs from IFRS valuation in the Group reporting; PY: kEUR 500), liabilities to affiliates in the amount of kEUR 3,364 (PY: kEUR 0) and to liabilities from the corporate bond in the amount of kEUR 131,241 (PY: kEUR 0; valuation according to German GAAP / Handelsgesetzbuch differs from IFRS valuation in the Group reporting). On February 19, 2024, LR SE placed a senior secured corporate bond (ISIN: NO0013149658) with a nominal issue volume of EUR 130 million and issue proceeds of approximately EUR 125 million. These proceeds were used to refinance the existing 2021/2025 bond of LR Global Holding GmbH (ISIN NO0010894850). In this context, a loan agreement was concluded between LR Global Holding GmbH and LR Health & Beauty SE on March 1, 2024. The bond is issued in the so-called "Nordic bond format" under Swedish law and with the involvement of Nordic Trustee & Agency AB as trustee. The bond bears interest at 7.5% + 3M EURIBOR (with a floor of zero) and matures on March 6, 2028. It is traded on the Open Market of the Frankfurt Stock Exchange. The terms of the corporate bond require a listing on the regulated market of Nasdaq Stockholm within twelve months of the issue date.

Cash flow from operating activities amounts to kEUR -2,207 in Q4 2024 (Q4 2023: kEUR 129) and to kEUR 1,756 in FY 2024 (FY 2023: kEUR -139). The cash flow from investing activities in Q4 2024 amounts to kEUR 5,823 (Q4 2023: kEUR 0) and

to kEUR -119,740 in the full year 2024, this includes the interest income from the intercompany loan issued to LR Global Holding GmbH in the amount kEUR 7,323 for Q4 2024 and kEUR 10,560 FY 2024, the issue of the intercompany loan in the amount of kEUR 128,800 as well as the payment for the assumption of losses from the profit and loss transfer agreement with LR Global Holding GmbH. The cash flow from financing activities in Q4 2024 comprises the interest payments for the corporate bond and amounts to kEUR -3,616 (Q4 2023: kEUR 0), while in the full year 2024, the proceeds from the corporate bond and from the shareholder loan are also included and thus amount in total to kEUR 117,842 (FY 2023: kEUR 0). Overall, total cash flow amounted to kEUR 0 in the fourth quarter of 2024 and to kEUR -141 in the full year, resulting in a cash balance of kEUR 0 as of December 31, 2024.

Munich, February 27, 2025

LR Health & Beauty SE
- Management Board -



Dr. Andreas Laabs
(CEO)



Andreas Grootz
(General Manager)

LR HEALTH & BEAUTY SE

UNAUDITED STATEMENT OF FINANCIAL POSITIONS
AS OF DECEMBER 31, 2024

kEUR	Dec. 31, 2024	Dec. 31, 2023
NON-CURRENT ASSETS		
Financial assets	281,273	152,458
thereof shares in affiliates	152,458	152,458
thereof loans to affiliates	128,815	0
	281,273	152,458
CURRENT ASSETS		
Receivables and other assets	1,146	619
thereof receivables from affiliates	1,067	619
Cash	0	141
	1,146	760
PREPAID EXPENSES	4,177	0
TOTAL ASSETS	286,596	153,218

UNAUDITED STATEMENT OF FINANCIAL POSITIONS
AS OF DECEMBER 31, 2024

kEUR	Dec. 31, 2024	Dec. 31, 2023
EQUITY		
Subscribed capital	10,120	10,120
Capital reserve	142,458	142,458
Accumulated loss	-12,252	-381
	140,326	152,197
PROVISIONS		
Tax provision	1,362	0
Other provisions	919	451
	2,281	451
LIABILITIES		
Liabilities from corporate bond	131,241	0
Trade payables	89	5
Liabilities to shareholders	4,016	500
Liabilities to affiliates	3,364	0
Other liabilities	55	65
	138,765	570
DEFERRED TAX LIABILITIES	5,224	0
TOTAL EQUITY AND LIABILITIES	286,596	153,218

LR HEALTH & BEAUTY SE

UNAUDITED STATEMENT FOR PROFIT AND LOSS FOR
THE PERIOD JAN. 1, 2024 TO DEC. 31, 2024

kEUR	Q4 2024	Q4 2023	FY 2024	FY 2023
Revenue	455	348	1,552	1,015
Other operating income	22	1	46	64
	477	349	1,598	1,079
Personnel expenses	362	253	1,537	951
thereof wages and salaries	354	243	1,500	930
thereof social security, pension and other benefit costs	8	10	37	21
Other operating expenses	198	4	1,563	211
	560	257	3,100	1,162
Other interest and similar income	3,354	0	11,507	0
Expenses from profit and loss transfer agreements	1,975	0	1,975	0
Other interest and similar expenses	3,918	0	13,289	0
	-2,539	0	-3,757	0
Income taxes	6,612	0	6,612	0
NET PROFIT/LOSS FOR THE PERIOD	-9,234	92	-11,871	-83

UNAUDITED STATEMENT OF CASH FLOWS FOR
THE PERIOD JAN. 1, 2024 TO DEC. 31, 2024

kEUR	Q4 2024	Q4 2023	FY 2024	FY 2023
CASHFLOW FROM OPERATING ACTIVITIES				
Profit or loss for the period	-9,234	92	-11,871	-83
Reduction (-)/Increase (+) in provisions	58	18	468	-653
Increase (-)/Reduction (+) of receivables and other assets	1,717	-12	2,925	857
Increase (+)/Reduction (-) of trade payables and other liabilities	-3,874	31	-111	-260
Interest expenses (+) / interest income (-)	2,540	0	3,758	0
Income tax expenses (+) / income (-)	6,612	0	6,612	0
Income tax paid (-)	-26	0	-26	0
	-2,207	129	1,756	-139
CASH FLOW FROM INVESTING ACTIVITIES				
Payments for (-) investments in financial assets	0	0	-128,800	0
Expenses (-) from profit and loss transfer agreements	-1,500	0	-1,500	0
Payments for (+) received interest	7,323	0	10,560	0
	5,823	0	-119,740	0
CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from (+) the issue of bonds	0	0	124,800	0
Proceeds from (+) shareholder loan	0	0	4,000	0
Payments (-) for interest	-3,616	0	-10,958	0
	-3,616	0	117,842	0
CASH AT THE END OF PERIOD				
Net increase in cash (subtotal 1 - 3)	0	129	-141	-139
Cash at the beginning of period	0	12	141	280
CASH AT THE END OF PERIOD	0	141	0	141

**WE
BELIEVE IN
A BRIGHT
FUTURE**

IMPRINT

Publisher:

LR Health & Beauty SE
Kruppstr. 55
D-59227 Ahlen

Management Board

Dr. Andreas Laabs (CEO),
Andreas Grootz

